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dol. Inclusion criteria of treatment episodes were that the sub-
jects were aged 18 years or above, had had at least one admis-
sion due to schizophrenia during the two-year period prior to
the initiation of the treatment episodes, and with no diabetes
mellitus during a one-year period prior to the initiation of the
treatment episodes. Diabetes mellitus was identiﬁed by claims
with such diagnosis or with antidiabetic agents. A logistic regres-
sion model was applied to evaluate the likelihood of newly-onset
cases of diabetes of different antipsychotic treatment episodes.
Patient and clinical characteristics were included as covariates.
RESULTS: Compared with users of haloperidol, those receiving
clozapine, olanzapine, and risperidone had a higher probability
of developing diabetes mellitus. Those taking quetiapine, amisul-
pride, and ziprasidone, however, had no signiﬁcantly higher 
odds of developing diabetes mellitus. CONCLUSIONS: The pre-
liminary ﬁndings of this study support reports of atypical
antipsychotics-induced diabetes mellitus. Clozapine, olanzapine,
and risperidone, compared with haloperidol, are associated with
an increased risk of diabetes mellitus among schizophrenic
patients in Taiwan.
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OBJECTIVES: Describe the annual direct health care and indi-
rect work loss costs for employees treated with antidepressants
and compare them across patients with different treatment
response. METHODS: We examined 1999–2003 data from a
claims database of 1.2 million beneﬁciaries, from 7 large U.S.
employers. Analysis was restricted to employees aged 18–64,
with at least one diagnosis of major depressive disorder (ICD-9:
296.2x, 296.3x) and at least one prescription of selective 
serotonin or seratonin/norepinephrine reuptake inhibitor
(SSRI/SNRI). Patients were classiﬁed as combination antidepres-
sant therapy users, switchers, discontinuers, or monotherapy
maintainers. Annual direct health care costs, including drug and
medical costs (comprising inpatient, outpatient, and emergency
visits), and indirect work loss costs (comprising absenteeism and
disability) were calculated for the 12-month period following
therapy initiation. Results were compared descriptively across
treatment responses using t-tests and ANOVA analyses.
RESULTS: Of the 3971 patients, 18.4% were on combination
therapy, 19.7% switchers, 45.1% discontinuers, and 16.8%
monotherapy maintainers. Patients on combination therapy had
similar direct and indirect costs compared to switchers (all p >=
0.08). The average direct and indirect costs for patients on com-
bination therapy and switchers ($7986 and $2806 respectively)
were higher than those for discontinuers ($6013 and $1680
respectively, all p < 0.001) or maintainers ($5193 and $1467
respectively, all p < 0.001). Compared to patients on combina-
tion therapy and switchers, maintainers had similar drug costs
($1980 vs. $2068, p = 0.469). Compared to discontinuers, main-
tainers had higher drug costs ($1,980 vs. $1095, p < 0.001), but
lower medical ($3214 vs. $4918, p = 0.002) and disability costs
($360 vs. $664, p = 0.008). CONCLUSION: Patients on 
combination therapy or who switched monotherapy had higher
average direct health care costs and indirect work loss costs than
patients who discontinued or maintained therapy. Maintainers
had higher drug costs but lower medical and disability costs 
compared to discontinuers.
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OBJECTIVE: To estimate the incremental cost-effectiveness of
venlafaxine extended-release compared to Selective Serotonin
Reuptake Inhibitors (SSRIs) in the treatment of major depressive
disorder (MDD) in Canada. METHODS: A previously validated
decision-tree model for the treatment of MDD was adapted 
to the Canadian clinical practice setting. Probabilities used to
populate the decision-tree were derived from the literature and
where needed, from a Delphi panel consisting of two General
Practitioners and two Psychiatrists. The Ontario Ministry of
Health and Long-term Care perspective was used in this study.
The relevant direct medical costs (year 2005 Canadian dollar
values) were derived from the Ontario Health Insurance Policy
(OHIP) and the Ontario Case Costing Initiative (OCCI). The
drug acquisition cost for venlafaxine (brand) and SSRIs (generic)
was derived from the Ontario Drug Beneﬁt formulary (ODB).
The treatment goal in the model was achieving remission and the
primary outcome measure in the model was Symptom Free Days
(SFDs). The time horizon was six months; therefore the costs and
outcomes were not discounted. Various one-way sensitivity
analyses were performed. RESULTS: The average six-month
expected cost per patient for venlafaxine and SSRIs were
CDN$4156 and CDN$4224 respectively. The average six-month
expected SFDs were 53.4 and 46.7 days for venlafaxine and
SSRIs respectively. The cost-effectiveness as measured by cost per
SFDs was CDN$77.86 for venlafaxine and CDN$90.36 for
SSRIs. The incremental cost-effectiveness analysis showed a
treatment strategy using venlafaxine as ﬁrst line was dominant.
The sensitivity analysis demonstrated the results robustness to
variations in drug acquisition cost. CONCLUSION: Despite a
higher drug acquisition cost, venlafaxine extended-release may
be cost-effective and even cost saving compared to SSRIs when
used as ﬁrst line treatment of MDD in a Canadian clinical 
practice setting.
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OBJECTIVES: To estimate the cost-effectiveness of atypical
antipsychotics (AAPs) in the treatment of acute mania in patients
with bipolar I disorder from a managed care perspective.
METHODS: The model estimated the cost-effectiveness (CE)
ratios for each AAP when used as monotherapy for the acute (3-
week) treatment of patients with bipolar mania. CE ratios were
deﬁned as the total annual cost per responder, and responders
were deﬁned as patients with a 50% improvement on the 
YMRS scale at 3 weeks. Data sources included published litera-
ture, package inserts, and primary data analysis of a managed
care claims database. The median response rate for each AAP
was used in the base case scenario; 45.5%, 50.0%, 58.0%,
53.3%, and 56.7% for aripiprazole, ziprasidone, risperidone,
quetiapine, and olanzapine, respectively. Since there are no pub-
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lished head to head comparisons between all AAPs, response
rates were obtained from individual studies for each AAP. Total
annual costs were calculated based on 1.3 acute manic episodes
per year and included costs of AAPs, concurrent medications,
adverse events, and medical resource utilization. All costs were
inﬂated to 2005 values. Incremental cost-effectiveness and sen-
sitivity analyses will be conducted. RESULTS: The total annual
costs per patient were $7897, $7778, $7807, $7730, and $7829
for aripiprazole, ziprasidone, risperidone, quetiapine, and 
olanzapine, respectively. Given the response rates and costs per
patient listed above, the CE ratios were $17,356, $15,555,
$13,360, $14,504, and $13,807, respectively. CONCLUSIONS:
These ﬁndings suggest that, among AAPs, treatment with risperi-
done may be the most cost-effective choice for acute manage-
ment of mania in patients with bipolar I disorder. The results of
this model are limited to a 3-week acute treatment of mania, thus
no conclusions can be drawn about the cost-effectiveness of
AAPs when used as maintenance treatment.
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OBJECTIVES: To assess changes in cost and effectiveness para-
meters following switch from risperidone to olanzapine during
the long-term treatment of schizophrenia patients. METHODS:
Patients were participants in a randomized, open-label, 1-year
cost-effectiveness trial of olanzapine, risperidone, and typical
antipsychotics in the treatment of schizophrenia. Study protocol
permitted antipsychotic switching when clinically warranted.
Resource utilization was systematically abstracted from medical
records. Treatment outcomes were assessed with standard 
psychiatric measures. Statistical analyses assessed changes from
pre-to-post switch among patients who were randomized to
risperidone, but later switched to olanzapine for any cause.
RESULTS: Sixty of the 218 (27.5%) patients randomized to
risperidone switched antipsychotics—with 43 (72%) switching
to olanzapine. Average duration on risperidone before switching
to olanzapine was 86.1 days (mean maximum dose 4.5mg/day).
Most of these switchers (86%) completed the 1-year study on
olanzapine (average maximum dose 13.3mg/day). Following
switch to olanzapine, patients experienced signiﬁcant improve-
ments on clinical and social parameters (both, p < 0.001), with
35.7% of the prior non-remitters achieving remission status.
Mean total daily costs changed from $49.5/day pre-switch, to
$44.4/day post-switch (non-signiﬁcant difference). CONCLU-
SIONS: Olanzapine appears to be a cost effective “rescue”
option for patients who require switching from risperidone in
the long-term treatment of schizophrenia.
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OBJECTIVES: Chronic schizophrenia is a high prevalence
disease in Mexico which generates signiﬁcant disabilities and
economic expenditures on the Mexican Health System. The
purpose of the study was to model the economic consequences
of adverse events (AE) related with ﬁve antipsychotic drugs in
adult patients in the Social Security Mexican Institute.
METHODS: A cost–effectiveness model was developed using a
Markov modeling approach. The model simulated treatment of
a cohort of 1000 schizophrenics for twelve months, initiating
treatment with one of ﬁve antipsychotic drugs; haloperidol (10
mg), ziprasidone (80mg), risperidone (4mg), olanzapine (15mg)
and clozapine (300mg). Conditional probabilities of developing
any AE (akathisia, weight gain, extrapyramidal symptoms) were
obtained according to clinical trials previously published and
were adjusted with local expert opinion surveys. Treatment was
susceptible to be modiﬁed (decrease dose, switch medication).
Effectiveness measure was the number of free months of psy-
chotic symptoms. The analysis was conducted from the health-
care payer’s perspective (only direct medical costs were used).
Resource use and costs were obtained from hospital records of
the biggest psychiatric hospital in Mexico (“Hospital San 
Fernando”). Probabilistic sensitivity analysis was performed 
and acceptability curves were constructed. RESULTS: Zipra-
sidone showed the lower expected annual costs per patient
(US$17,159.5 ± 7,605.1) and the higher number of free months
of psychotic symptoms (9.2 ± 1.5 months). Ziprasidone was 
followed by risperidone and clozapine who obtained annual
expected costs of US$19,589.2 and US$24,656.1; and effective-
ness of 8.8 and 8.9 months, respectively. Results were robust to
Monte Carlo second order sensitivity analysis. Acceptability
curves showed the same results with a mean of 60% of certainty.
CONCLUSIONS: In Mexico, ziprasidone resulted the treatment
most cost–effective, followed by risperidone, clozapine and olan-
zapine. These results should be taken into account by Mexican
decision makers and clinicians in the management of patients
with chronic schizophrenia.
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OBJECTIVES: This study examined health care and resource 
utilization associated with atypical antipsychotic treatment for
bipolar disorder. METHODS: Using the NC Medicaid Claims
database 3328 patients were identiﬁed who had 3 months pre-
and 12 months post-treatment initiation data. Patients diagnosed
with bipolar disorder were classiﬁed into three groups based on
type of treatment during the ﬁrst 30 days after treatment initia-
tion (index date): atypical antipsychotic (AP2) monotherapy,
atypical antipsychotic plus mood stabilizer (AP2 + MS) combi-
nation therapy, and mood stabilizer (MS) monotherapy. For the
12 month treatment period, total bipolar-related and total
health-related costs were examined including and excluding
index medication. Comparative costs of index medications were
also analyzed. Propensity score matching was employed to
balance baseline characteristics between the three comparison
groups. Gamma regression models were further employed to 
estimate the average treatment effect on the cost outcomes.
RESULTS: Compared to MS monotherapy, AP2 monotherapy
and AP2 + MS therapy incurred higher index medication costs
during the treatment period. Patients on AP2 monotherapy
incurred signiﬁcantly lower total health-related costs excluding
index medication (-10.9%, p < 0.046), leading to no statistical
difference in total health-related cost including index medication
(1.5%, p < 0.76). In terms of total bipolar-related costs, patients
on AP2 monotherapy had higher costs than MS monotherapy
when including index medication costs (14.9%, p < 0.01).
However, bipolar-related costs excluding index medication cost
was signiﬁcantly lower (-16.7%, p < 0.03). Results were similar
